Cancer of the renal pelvis or ureter is cancer that forms in the kidney's pelvis or the tube that carries urine from the kidney to the bladder.
Cancer can grow in the urine collection system, but is uncommon. As a group, renal pelvis and ureter cancers account for about 5% of all cancers of the kidney and upper urinary tract. They affect men more often than women and are more common in people older than 65.
Tumors of the renal pelvis and ureter are usually transitional cell cancers. Approximately 10% are squamous cell carcinomas.
The causes of this cancer are not completely known. Long-term (chronic) irritation of the kidney from harmful substances removed in the urine may be a factor. This irritation may be caused by:
Patients with a history of bladder cancer are also at risk.
The health care provider will perform a physical exam, and examine your belly area (abdomen). In rare cases, this may reveal an enlarged kidney.
The following tests may be done:
These tests may reveal a tumor or show that the cancer has spread from the kidneys.
The goal of treatment is to eliminate the cancer.
Surgery to remove all or part of the kidney (nephrectomy) is usually recommended. This may include removing part of the bladder and tissues around it, or the lymph nodes. If the tumor is in the ureter, it may be possible to remove it while preserving the kidney.
When the cancer has spread outside of the kidney or ureter, chemotherapy is often used. Because these tumors are similar to a form of bladder cancer, they are treated with a similar type of chemotherapy.
For additional information and resources, see cancer support groups.
The outcome varies depending on the location of the tumor and whether the cancer has spread. Cancer that is only in the kidney or ureter can be cured with surgery.
Cancer that has spread to other organs is usually not curable. However, there are exceptions.
Call your health care provider if you have the symptoms listed above.
Transitional cell cancer of the renal pelvis or ureter
Bajorin DF. Tumors of the kidney, bladder, ureters, and renal pelvis. In Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Philadelphia, PA: Saunders Elsevier; 2011:chap 203.
National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Bladder cancer. 2012. Version 2.2012.
Updated by: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 1997-2012, A.D.A.M., Inc. Duplication for commercial use must be authorized in writing by ADAM Health Solutions.